- EDAP has developed an innovative HIFU treatment device for prostate and other cancers, which it was already selling.
- The offering is boosted by an exclusive distribution deal with the maker of a complementary device and the upcoming Category 1 CPT reimbursement code.
- The shares are a steal unless the COVID-19 pandemic worsens, as the company’s sales and finances are greatly affected by the pandemic.
EDAP Shares Are Still A Steal, But The Pandemic Could Be A Wrench
June 7th, 2020 · No Comments